Ovarian Cancer Therapeutics Market By Drug Class (PARP Inhibitors, Platinum-Based Chemotherapy, Taxanes, VEGF/Anti-Angiogenic Agents, Antibody-Drug Conjugates, Immunotherapies, Other Drug Classes); By Therapy Type (Targeted Therapy, Chemotherapy, Immunotherapy, Hormone Therapy, Other Therapies and Combination Regimens); By Disease Indication (Epithelial Ovarian Cancer, Fallopian Tube and Primary Peritoneal Cancer, Rare Ovarian Tumors); By Distribution Channel (Hospital Pharmacies, Specialty Pharmacies, Retail and Online Pharmacies); By Geography, Segment Revenue Estimation, Forecast, 2026–2032

Ovarian Cancer Therapeutics Market Shifts Toward Biomarker-Led Treatment

The Global Ovarian Cancer Therapeutics Market was valued at USD 4.12 billion in 2025 and is projected to reach USD 6.43 billion by 2032, expanding at a CAGR of 6.57% during 2026–2032, according to Strategic Market Research.

 

The Ovarian Cancer Therapeutics Market refers to the global market for pharmaceutical treatments used to treat, control, and prevent recurrence of ovarian cancer, including closely managed fallopian-tube and primary peritoneal cancers. It primarily captures drug revenues from chemotherapy, PARP inhibitors, anti-angiogenic therapies, antibody-drug conjugates (ADCs), immunotherapies, hormone therapies, and other targeted agents, while surgery, diagnostics, radiotherapy, and hospitalization are generally excluded.

 

Ovarian cancer remains a major gynecologic oncology burden approx. 324,603 new cases and 206,956 deaths worldwide in 2022. In the United States, the American Cancer Society estimates 21,010 new cases and 12,450 deaths in 2026, while approximately 9 in 10 cases are epithelial ovarian cancers. U.S. SEER data show that 54% of patients are diagnosed with distant disease, compared with 22% at a localized stage and 18% at a regional stage, supporting substantial demand for systemic therapies.

 

The treatment landscape is expanding rapidly with platinum-based chemotherapy, particularly carboplatin plus paclitaxel, followed in eligible patients by maintenance or targeted therapy. Major marketed therapies include AstraZeneca’s Lynparza (olaparib), GSK’s Zejula (niraparib), Roche/Genentech’s Avastin (bevacizumab), and AbbVie’s Elahere (mirvetuximab soravtansine). Elahere has established ADC therapy for FRα-positive, platinum-resistant disease.

 

Approximately 80% of epithelial ovarian, fallopian-tube, and primary peritoneal cancer patients relapse after first-line platinum- and taxane-based chemotherapy. In the supplied market model, global incidence increases from approximately 339,070 cases in 2025 to 384,350 by 2032, while pharmaceutical revenue rises substantially faster. Treatment intensity, recurrent therapy, biomarker testing, maintenance treatment, and higher-value targeted drugs therefore account for much of the revenue expansion. PARP inhibitors are estimated to represent about 57% of 2025 market revenue.

 

In May 2025, the FDA approved avutometinib plus defactinib for KRAS-mutated recurrent low-grade serous ovarian cancer, reporting a 44% confirmed response rate. In February 2026, Keytruda (pembrolizumab) plus paclitaxel, with or without bevacizumab, was approved for PD-L1-positive platinum-resistant disease. In March 2026, Corcept’s Lifyorli (relacorilant) plus nab-paclitaxel gained FDA approval. Meanwhile, Daiichi Sankyo and Merck’s investigational CDH6-directed ADC raludotatug deruxtecan achieved a 50.5% objective response rate in Phase 2 and is advancing through Phase 3 evaluation.

 

Overall, the Ovarian Cancer Therapeutics Market is shifting from chemotherapy-centered management toward biomarker-guided maintenance, ADCs, immunotherapy combinations, and precision therapies, with late-stage diagnosis, high recurrence, companion diagnostics, and expanding targeted-treatment options shaping future pharmaceutical spending.

 

PARP Maintenance Leads Revenue as Immunotherapy Accelerates

By Drug Class – PARP Inhibitors Hold the Revenue Base While Immunotherapy Accelerates

Leading Subsegment – PARP Inhibitors

PARP inhibitors dominate the ovarian cancer therapeutics drug-class segment, holding an estimated 57% share and generating USD 2.348 billion in 2025. With a projected CAGR of 4.20% from 2026 to 2032, revenue could reach nearly USD 3.13 billion by 2032. Their strong position reflects broad use in maintenance therapy, particularly for BRCA-mutated and HRD-positive tumors. Drugs such as olaparib, niraparib, and rucaparib exploit DNA-repair weaknesses, while combination strategies are being studied to extend treatment response and address resistance.

Fastest-Growing Subsegment – Immunotherapy

Immunotherapy accounted for an estimated 4% of the Ovarian Cancer Therapeutics Market in 2025, generating about USD 0.165 billion, and is projected to grow at nearly 20.0% CAGR through 2032, reaching approximately USD 0.59 billion. Current treatment strategies focus on immune checkpoint inhibitors such as pembrolizumab and dostarlimab, particularly for biomarker-selected patients. Combination regimens involving PARP inhibitors and anti-angiogenic therapies, along with emerging CAR-T cell therapies and cancer vaccines, are expanding the future immunotherapy opportunity.

 

By Therapy Type – Targeted Medicines Dominate as Immunotherapy Opens a New Treatment Layer

Leading Subsegment – Targeted Therapy

Targeted therapy holds nearly 74% of the Ovarian Cancer Therapeutics Market, generating about USD 3.049 billion in 2025, and is projected to grow at a CAGR of 6.30% to approximately USD 4.68 billion by 2032. Treatment increasingly centers on PARP inhibitors such as olaparib and niraparib, anti-angiogenic drugs including bevacizumab, and FRα-targeted antibody-drug conjugates such as mirvetuximab soravtansine. BRCA, HRD, and FRα testing is expanding personalized treatment selection across maintenance and recurrent ovarian cancer.

Fastest-Growing Subsegment – Immunotherapy

Immunotherapy accounted for an estimated 4% of the Ovarian Cancer Therapeutics Market in 2025, generating about USD 0.165 billion, and is projected to grow at nearly 20.0% CAGR through 2032, reaching approximately USD 0.59 billion. Current treatment strategies focus on immune checkpoint inhibitors such as pembrolizumab and dostarlimab, particularly for biomarker-selected patients. Combination regimens involving PARP inhibitors and anti-angiogenic therapies, along with emerging CAR-T cell therapies and cancer vaccines, are expanding the future immunotherapy opportunity.

 

By Disease Indication – Epithelial Disease Controls Spending While Related Müllerian Cancers Expand

Leading Subsegment – Epithelial Ovarian Cancer

Epithelial ovarian cancer leads the disease-indication segment with an estimated 92% share, generating approximately USD 3.790 billion in 2025. With a projected CAGR of 6.53%, revenue could reach nearly USD 5.90 billion by 2032. Its large patient base supports strong demand for platinum-taxane chemotherapy, PARP inhibitors, bevacizumab, and newer antibody-drug conjugates. Treatment expansion is increasingly shaped by BRCA and HRD testing, maintenance therapy adoption, and targeted options for platinum-resistant disease.

Fastest-Growing Subsegment – Fallopian Tube and Primary Peritoneal Cancer

Fallopian-tube and primary peritoneal cancers account for an estimated 6% of the Ovarian Cancer Therapeutics Market, representing USD 0.247 billion in 2025 revenue. With a projected CAGR of 7.60%, the segment could reach approximately USD 0.41 billion by 2032. Their close biological relationship with high-grade serous ovarian cancer supports common treatment pathways, including cytoreductive surgery, platinum-based chemotherapy, PARP inhibitors, and bevacizumab. Shared BRCA1/2 and p53 abnormalities continue to shape targeted-treatment strategies and maintenance treatment decisions across these related gynecologic cancers.

 

By Distribution Channel – Hospitals Control Infusions While Specialty Pharmacies Gain from Long-Term Oral Therapy

Leading Subsegment – Hospital Pharmacies

Hospital pharmacies represent about 62% of ovarian cancer therapeutics revenue, equal to nearly USD 2.554 billion in 2025, and could reach around USD 3.80 billion by 2032 at a modeled 5.85% CAGR. Their strong position reflects the hospital-based delivery of platinum chemotherapy, bevacizumab, and other infusion therapies, along with specialist oversight of PARP inhibitors and supportive medicines. Oncology pharmacists also support dose management, toxicity monitoring, drug-interaction checks, and treatment adherence across complex ovarian cancer regimens during active and maintenance treatment.

Fastest-Growing Subsegment – Specialty Pharmacies

Specialty pharmacies account for approximately 29% of the Ovarian Cancer Therapeutics Market, generating USD 1.195 billion in 2025, and are projected to grow at the fastest distribution-channel CAGR of 7.90% during 2026–2032, reaching more than USD 2.03 billion by 2032. Their role is expanding as ovarian cancer treatment increasingly includes oral targeted therapies. These pharmacies support access to PARP inhibitors, manage prior authorizations and financial assistance, monitor adherence and treatment-related toxicities, and coordinate care between patients, oncologists, and insurers effectively.

 

By Geography – North America Leads Revenue While Asia-Pacific Holds the Largest Patient Pool

Leading Subsegment – North America

North America dominates the ovarian cancer therapeutics market, accounting for an estimated 45% share and USD 1.854 billion in revenue in 2025. With a modeled CAGR of 6.0%, regional revenue is projected to reach nearly USD 2.79 billion by 2032. Market growth is supported by the established use of platinum-based chemotherapy, PARP inhibitors, bevacizumab, and newer biomarker-directed therapies. Expanding BRCA and HRD testing is also strengthening treatment selection and maintenance-therapy adoption, while the introduction of folate receptor alpha-targeted therapies is widening treatment options for patients with recurrent ovarian cancer.

Fastest-Growing Subsegment – Asia-Pacific

Asia-Pacific accounted for an estimated 22% of the global Ovarian Cancer Therapeutics Market, generating approximately USD 0.906 billion in 2025. The region is projected to register the fastest CAGR of around 8.60% during 2026–2032, taking revenue to nearly USD 1.61 billion by 2032. Growth is supported by the rising ovarian cancer burden, wider BRCA and HRD testing, increasing use of PARP inhibitors as maintenance therapy, and growing adoption of targeted treatments alongside platinum-based chemotherapy and bevacizumab across major Asian healthcare markets.

 

New Approvals Expand the Precision Treatment Toolkit

Ovarian cancer treatment is moving beyond conventional platinum chemotherapy and PARP maintenance toward biomarker-selected immunotherapies, ADCs, kinase inhibitors, and resistance-targeting combinations. Several recent approvals are widening treatment choices for patients with recurrent or platinum-resistant disease.

• Pembrolizumab (Keytruda) + paclitaxel: In February 2026, the FDA approved pembrolizumab with paclitaxel, with or without bevacizumab, for PD-L1-positive (CPS ≥1) platinum-resistant epithelial ovarian, fallopian-tube, or primary peritoneal cancer after one or two prior systemic regimens. In KEYNOTE-B96, median overall survival reached 18.2 months versus 14.0 months with chemotherapy-based control, while progression-free survival was 8.3 months versus 7.2 months. This creates a new biomarker-defined immunotherapy opportunity in a setting where checkpoint inhibitors historically had limited use.

• Relacorilant (Lifyorli) + nab-paclitaxel: Approved in March 2026 for previously treated platinum-resistant ovarian cancer after prior bevacizumab, this combination targets glucocorticoid-receptor-mediated treatment resistance. In the 381-patient ROSELLA study, median overall survival improved to 16.0 months from 11.9 months, while progression-free survival increased to 6.5 months from 5.5 months.

• Avutometinib + defactinib: This oral RAF/MEK and FAK inhibitor combination received FDA accelerated approval in 2025 for KRAS-mutated recurrent low-grade serous ovarian cancer, a relatively rare subtype with different biology from high-grade serous disease. The RAMP-201 study reported a 44% objective response rate, with 88% of responding patients maintaining their response for at least six months.

• Mirvetuximab soravtansine (Elahere): This FRα-targeted antibody-drug conjugate represents one of the most important shifts toward precision treatment in platinum-resistant ovarian cancer. In the MIRASOL trial, Elahere produced a 42% response rate versus 16% with chemotherapy and improved median overall survival to 16.5 months from 12.7 months. Its full FDA approval in 2024 established FRα testing as an increasingly important treatment-selection tool.

Together, these treatments are expanding the ovarian cancer therapeutics market from broadly administered chemotherapy toward PD-L1-, FRα-, and KRAS-directed treatment pathways. This shift is particularly important commercially because recurrent disease affects a large patient pool and increasingly requires biomarker testing followed by higher-value targeted or combination therapies.

 

Lynparza and Zejula Anchor the Maintenance-Therapy Field

AstraZeneca – Lynparza Maintains a Major Position in Biomarker-Directed Ovarian Cancer Therapy

AstraZeneca remains one of the most established companies in ovarian cancer therapeutics through Lynparza (olaparib), its PARP inhibitor developed with Merck. Lynparza is used as maintenance treatment for selected patients with advanced epithelial ovarian, fallopian-tube, or primary peritoneal cancer, particularly patients carrying BRCA1/2 mutations. The FDA approved Lynparza for first-line maintenance treatment of BRCA-mutated advanced ovarian cancer following response to platinum chemotherapy in 2018.

Lynparza generated approximately USD 3.28 billion in worldwide product sales in 2025 across all of its approved cancer indications, compared with USD 3.07 billion in 2024. U.S. sales reached USD 1.43 billion, Europe generated USD 914 million, emerging markets contributed USD 669 million, and established rest-of-world markets contributed about USD 262 million. AstraZeneca specifically reported continued gains in first-line ovarian cancer in several markets, although Lynparza's total sales also include breast, prostate, pancreatic, and other approved uses.

The drug's commercial importance in ovarian cancer comes from its position in maintenance treatment, where eligible patients can remain on therapy following platinum chemotherapy rather than receiving treatment only during active chemotherapy cycles.

GSK – Zejula Supports a Large PARP-Inhibitor Maintenance Franchise

GSK is another major established participant through Zejula (niraparib), an oral PARP inhibitor used primarily in ovarian cancer maintenance therapy. Zejula gives GSK a direct presence in patients who have responded to platinum-based chemotherapy and require treatment intended to delay disease progression or recurrence.

GSK reported GBP 557 million in Zejula sales during 2025, compared with GBP 593 million in 2024. The company's overall oncology business generated approximately GBP 1.98 billion in 2025, with Zejula remaining one of its principal oncology products alongside Jemperli and Ojjaara/Omjjara. GSK reported that Zejula continues to serve ovarian cancer patients across the United States, Europe, and international markets, although current use is increasingly concentrated within defined eligible patient groups.

The commercial role of Zejula remains centered on PARP-based maintenance, giving GSK exposure to the large recurrent and post-platinum ovarian cancer population.

ADC and Immunotherapy Players Expand the Competitive Field

• AbbVie: Owns Elahere (mirvetuximab soravtansine), an FRα-targeted ADC for FRα-positive platinum-resistant ovarian cancer; Elahere generated USD 690 million in 2025 global revenue, up 43%, making ADC therapy an increasingly important commercial segment.

• Roche/Genentech: Supplies Avastin (bevacizumab), a VEGF inhibitor widely incorporated into ovarian cancer chemotherapy and maintenance combinations; Roche reported CHF 973 million in total Avastin sales across cancer indications in 2025.

• Merck & Co.: Expanded into ovarian cancer through Keytruda (pembrolizumab), FDA-approved in February 2026 with paclitaxel, with or without bevacizumab, for PD-L1-positive platinum-resistant ovarian cancer after one or two previous systemic regimens.

• Verastem Oncology: Commercializes Avmapki Fakzynja Co-Pack (avutometinib + defactinib), FDA-approved in 2025 for previously treated KRAS-mutated recurrent low-grade serous ovarian cancer, opening a targeted treatment segment for this rare subtype.

• Corcept Therapeutics: Entered the ovarian cancer treatment market with Lifyorli (relacorilant) plus nab-paclitaxel, approved by the FDA in March 2026 for previously treated platinum-resistant disease; the ROSELLA trial showed median overall survival of 16.0 months versus 11.9 months with nab-paclitaxel alone.

• Daiichi Sankyo and Merck: Are developing next-generation antibody-drug conjugates, including raludotatug deruxtecan, as part of efforts to expand targeted ADC treatment into additional biomarker-defined ovarian cancer populations.

 

Analyst View: Biomarker Selection Sets the Next Growth Path

The ovarian cancer therapeutics market is shifting from chemotherapy-led treatment toward biomarker-driven and targeted approaches. Growing use of BRCA, HRD, FRα, PD-L1, and KRAS testing is helping clinicians identify patients for PARP inhibitors, antibody-drug conjugates, immunotherapies, and targeted kinase combinations. The next phase of market development is expected to be shaped by therapies for recurrent and platinum-resistant disease, where treatment needs remain high.

 

Ovarian Cancer Therapeutics Market Report Coverage Table

Report Attribute	Details
Forecast Period	2026 – 2032
Market Size Value in 2025	USD 4.12 Billion
Revenue Forecast in 2032	USD 6.43 Billion
Overall Growth Rate	CAGR of 6.57% (2026–2032)
Base Year for Estimation	2025
Historical Data	2019 – 2024
Unit	USD Million/Billion, CAGR (2026–2032)
Segmentation	By Drug Class, By Therapy Type, By Disease Indication, By Distribution Channel, By Geography
By Drug Class	PARP Inhibitors, Platinum-Based Chemotherapy, Taxanes, VEGF/Anti-Angiogenic Agents, Antibody-Drug Conjugates (ADCs), Immunotherapies, Other Drug Classes
By Therapy Type	Targeted Therapy, Chemotherapy, Immunotherapy, Hormone Therapy, Other Therapies and Combination Regimens
By Disease Indication	Epithelial Ovarian Cancer, Fallopian Tube and Primary Peritoneal Cancer, Rare Ovarian Tumors
By Distribution Channel	Hospital Pharmacies, Specialty Pharmacies, Retail and Online Pharmacies
By Geography	North America, Europe, Asia-Pacific, Latin America, Middle East & Africa
Country Scope	U.S., Canada, Germany, France, Netherlands, China, India, South Korea, Japan, Brazil, Mexico, UAE, Saudi Arabia, South Africa
Market Drivers	Treatment intensity, recurrent therapy, biomarker testing, maintenance treatment, and higher-value targeted drugs therefore account for much of the revenue expansion.
Customization Option	Available upon request